Friday, 16 October 2026European Markets

NORTHERN DRILLING Stock 10.81% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with NORTHERN DRILLING (NODL.OL) rising 10.81% to kr0.41 on Friday while Oslo Børs Benchmark Index_GI dropped 0.59% to kr1,271.69.

NORTHERN DRILLING's last close was kr0.37, 98.94% below its 52-week high of kr34.90.

About NORTHERN DRILLING

Earnings Per Share

As for profitability, NORTHERN DRILLING has a trailing twelve months EPS of kr-5.85.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -4.22%.

Volume

Today's last reported volume for NORTHERN DRILLING is 139865 which is 95.67% below its average volume of 3234080.

Yearly Top and Bottom Value

NORTHERN DRILLING's stock is valued at kr0.41 at 21:32 EST, way under its 52-week high of kr34.90 and way above its 52-week low of kr0.31.

Volatility

NORTHERN DRILLING's last week, last month's, and last quarter's current intraday variation average was a negative 0.82%, a negative 3.96%, and a positive 12.69%.

NORTHERN DRILLING's highest amplitude of average volatility was 1.92% (last week), 4.81% (last month), and 12.69% (last quarter).

Moving Average

NORTHERN DRILLING's worth is way under its 50-day moving average of kr1.53 and way below its 200-day moving average of kr16.16.

More news about NORTHERN DRILLING (NODL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com